Key Insights

Highlights

Success Rate

90% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

3.4%

1 terminated out of 29 trials

Success Rate

90.0%

+3.5% vs benchmark

Late-Stage Pipeline

24%

7 trials in Phase 3/4

Results Transparency

33%

3 of 9 completed with results

Key Signals

3 with results90% success

Data Visualizations

Phase Distribution

21Total
Not Applicable (5)
Early P 1 (1)
P 1 (4)
P 2 (4)
P 3 (5)
P 4 (2)

Trial Status

Completed9
Recruiting8
Active Not Recruiting4
Not Yet Recruiting3
Unknown2
Terminated1

Trial Success Rate

90.0%

Benchmark: 86.5%

Based on 9 completed trials

Clinical Trials (29)

Showing 20 of 20 trials
NCT03816345Phase 1Recruiting

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

NCT02450396Withdrawn

Pregnancy and Medically Assisted Conception in Rare Diseases

NCT06875102Not ApplicableRecruitingPrimary

Fatigue in Sjögren's Syndrome: 3 Therapeutic Strategies

NCT05350072Phase 3Active Not RecruitingPrimary

Two-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome

NCT05349214Phase 3Active Not RecruitingPrimary

Three-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome

NCT07153276Phase 4RecruitingPrimary

TREATMENT OF VAGINAL DRYNESS IN SJÖGREN'S DISEASE WITH CO2-LASER VERSUS TOPICAL PROMESTRIENE

NCT05124925Phase 2CompletedPrimary

Biopsy Based Study to Understand Mechanism of Action of Ianalumab in Salivary Glands and Explore Relationships With Clinical Assessments.

NCT07301164Early Phase 1Not Yet Recruiting

Clinical Study of BCT301 Cell Injection Therapy for Refractory Autoimmune Diseases

NCT06991114Phase 2Recruiting

AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.

NCT07249060Recruiting

Interferon Signature in Anti-CTLA-4 and Anti-PD-1/PD-L1-Treated Cancer Patients Compared With Systemic Autoimmune Disease Patients

NCT07248436CompletedPrimary

"Validity and Reliability of Pelvic Floor Distress Inventory-20 in Primary Sjögren's Syndrome"

NCT07248306CompletedPrimary

Temporomandibular Joint Dysfunction in Sjögren's Syndrome

NCT06626477Not ApplicableCompletedPrimary

Intra-Nasal Mechanical Stimulation (INMEST) as a Potential Treatment Method for Sjogren's Syndrome (SS)

NCT06828042Phase 1Recruiting

Safety and Efficacy of Universal CD19-targeting CAR-γδT Cells in Refractory Autoimmune Diseases

NCT06877546Not ApplicableActive Not RecruitingPrimary

Photodynamic Treatment as Part of Oral Healthcare on Persons With Sjögren's Syndrome

NCT06931041Phase 3Active Not Recruiting

Comparing Efficacy of Autologous Serum Eye Drops With and Without Insulin in Autoimmune Dry Eye: A Randomized Clinical Trial

NCT06794008Phase 2Recruiting

BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases

NCT06879444Enrolling By InvitationPrimary

"Core Stabilization Strenght and Pelvic Floor Functions in Primary Sjogren's"

NCT06821659Phase 1Not Yet Recruiting

Safety and Efficacy of Universal CAR-T Cells (UWD-CD19) Combined with Immunosuppressants in the Treatment of Refractory Autoimmune Diseases

NCT06740175Not ApplicableCompletedPrimary

The Feasibility of Multispectral Optoacoustic Tomography in Different Diseases

Scroll to load more

Research Network

Activity Timeline